🚀 VC round data is live in beta, check it out!
- Public Comps
- THX Pharma
THX Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for THX Pharma and similar public comparables like LTR Pharma, Herantis Pharma, Kezar Life Sciences, Mereo BioPharma Group and more.
THX Pharma Overview
About THX Pharma
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company’s therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson’s disease, THN201 for the treatment of neurocognitive disorders in Alzheimer’s disease and THN101 for neuropathic pain.
Founded
2013
HQ

Employees
15
Website
Sectors
Financials (FY)
EV
$54M
THX Pharma Financials
THX Pharma reported last fiscal year revenue of — and negative EBITDA of ($3M).
In the same fiscal year, THX Pharma generated ($3M) in gross profit, ($3M) in EBITDA losses, and had net loss of ($2M).
Revenue (LTM)
THX Pharma P&L
In the most recent fiscal year, THX Pharma reported revenue of — and EBITDA of ($3M).
THX Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | — | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| Net Profit | $4M | XXX | ($2M) | XXX | XXX | XXX |
| Net Debt | — | — | $3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
THX Pharma Stock Performance
THX Pharma has current market cap of $53M, and enterprise value of $54M.
Market Cap Evolution
THX Pharma's stock price is $3.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $54M | $53M | 2.4% | XXX | XXX | XXX | $-0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTHX Pharma Valuation Multiples
THX Pharma trades at (18.9x) EV/EBITDA.
EV / Revenue (LTM)
THX Pharma Financial Valuation Multiples
As of April 11, 2026, THX Pharma has market cap of $53M and EV of $54M.
Equity research analysts estimate THX Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
THX Pharma has a P/E ratio of 13.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $53M | XXX | $53M | XXX | XXX | XXX |
| EV (current) | $54M | XXX | $54M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (18.9x) | XXX | XXX | XXX |
| EV/EBIT | 18.5x | XXX | (19.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (17.4x) | XXX | XXX | XXX |
| P/E | 13.5x | XXX | (29.3x) | XXX | XXX | XXX |
| EV/FCF | 14.6x | XXX | (25.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified THX Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


THX Pharma Margins & Growth Rates
THX Pharma's revenue in the last fiscal year grew by —.
THX Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $-0.0M for the same period.
THX Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (66%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $-0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
THX Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Herantis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Kezar Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Mereo BioPharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| MiNK Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
THX Pharma M&A Activity
THX Pharma acquired XXX companies to date.
Last acquisition by THX Pharma was on XXXXXXXX, XXXXX. THX Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by THX Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTHX Pharma Investment Activity
THX Pharma invested in XXX companies to date.
THX Pharma made its latest investment on XXXXXXXX, XXXXX. THX Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by THX Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout THX Pharma
| When was THX Pharma founded? | THX Pharma was founded in 2013. |
| Where is THX Pharma headquartered? | THX Pharma is headquartered in France. |
| How many employees does THX Pharma have? | As of today, THX Pharma has over 15 employees. |
| Is THX Pharma publicly listed? | Yes, THX Pharma is a public company listed on Euronext Paris. |
| What is the stock symbol of THX Pharma? | THX Pharma trades under ALTHX ticker. |
| When did THX Pharma go public? | THX Pharma went public in 2017. |
| Who are competitors of THX Pharma? | THX Pharma main competitors are LTR Pharma, Herantis Pharma, Kezar Life Sciences, Mereo BioPharma Group. |
| What is the current market cap of THX Pharma? | THX Pharma's current market cap is $53M. |
| Is THX Pharma profitable? | Yes, THX Pharma is net-income-positive (as of the last 12 months). |
| What is the current net income of THX Pharma? | THX Pharma's last 12 months net income is $4M. |
| What is the current FCF of THX Pharma? | THX Pharma's last 12 months FCF is $4M. |
| What is the current EV/FCF multiple of THX Pharma? | Current FCF multiple of THX Pharma is 14.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.